{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T13:39:11Z","timestamp":1649165951570},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00120-015-4009-7","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T04:09:45Z","timestamp":1450930185000},"page":"1758-1764","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemische Tumortherapie bei \u00e4lteren Patienten"],"prefix":"10.1007","volume":"54","author":[{"given":"J.","family":"Hess","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,20]]},"reference":[{"key":"4009_CR1","unstructured":"Kuhlmey A, Schaeffer D (2008) Alter, Gesundheit und Krankheit \u2013 Handbuch Gesundheitswissenschaften. Huber, Bern"},{"key":"4009_CR2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.ejca.2010.02.022","volume":"46","author":"Pallis","year":"2010","unstructured":"Pallis AG, Fortpied C, Wedding U et al (2010) EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 46(9):1502\u20131513","journal-title":"Eur J Cancer"},{"key":"4009_CR3","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","volume":"27","author":"Smith","year":"2009","unstructured":"Smith BD, Smith GL, Hurria A et al (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758\u20132765","journal-title":"J Clin Oncol"},{"key":"4009_CR4","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","volume":"29","author":"Hurria","year":"2011","unstructured":"Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457\u20133465","journal-title":"J Clin Oncol"},{"key":"4009_CR5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1200\/JCO.2004.08.136","volume":"22","author":"Earle","year":"2004","unstructured":"Earle CC, Neville BA, Landrum MB et al (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22(2):315\u2013332","journal-title":"J Clin Oncol"},{"key":"4009_CR6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1996.14.2.671","volume":"14","author":"o","year":"1996","unstructured":"o A (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 14(2):671\u2013679","journal-title":"J Clin Oncol"},{"key":"4009_CR7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0959-8049(99)00319-6","volume":"36","author":"Extermann","year":"2000","unstructured":"Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36(4):453\u2013471","journal-title":"Eur J Cancer"},{"key":"4009_CR8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.10762","volume":"95","author":"Bellmunt","year":"2002","unstructured":"Bellmunt J, Albanell J, Paz-Ares L et al (2002) Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I\/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95(4):751\u2013757","journal-title":"Cancer"},{"key":"4009_CR9","unstructured":"Beauchamps TL, Childress JF (2009) Principles of biomedical ehtics, 6.\u00a0Aufl. Oxford University Press, Oxford"},{"key":"4009_CR10","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00120-013-3212-7","volume":"52","author":"Wedding","year":"2013","unstructured":"Wedding U (2013) Geriatric assessment prior to oncological therapy. Urologe A 52(6):827\u2013831","journal-title":"Urologe A"},{"key":"4009_CR11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/1756-0500-3-200","volume":"3","author":"Porock","year":"2010","unstructured":"Porock D, Parker-Oliver D, Petroski GF, Rantz M (2010) The MDS Mortality Risk Index: the evolution of a method for predicting 6-month mortality in nursing home residents. BMC Res Notes 3:200","journal-title":"BMC Res Notes"},{"key":"4009_CR12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2013.51.1345","volume":"32","author":"Kenis","year":"2014","unstructured":"Kenis C, Decoster L, Van Puyvelde K et al (2014) Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol 32(1):19\u201326","journal-title":"J Clin Oncol"},{"key":"4009_CR13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<760::AID-CNCR20>3.0.CO;2-V","volume":"82","author":"Repetto","year":"1998","unstructured":"Repetto L, Venturino A, Vercelli M et al (1998) Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 82(4):760\u2013765","journal-title":"Cancer"},{"key":"4009_CR14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.archger.2010.10.021","volume":"52","author":"Tognoni","year":"2011","unstructured":"Tognoni P, Simonato A, Robutti N et al (2011) Preoperative risk factors for postoperative delirium (POD) after urological surgery in the elderly. Arch Gerontol Geriatr 52(3):166\u2013169","journal-title":"Arch Gerontol Geriatr"},{"key":"4009_CR15","doi-asserted-by":"crossref","first-page":"11266","DOI":"10.1371\/journal.pone.0011266","volume":"5","author":"Almeida","year":"2010","unstructured":"Almeida OP, Alfonso H, Hankey GJ, Flicker L (2010) Depression, antidepressant use and mortality in later life: the Health In Men Study. PLoS One 5(6):11266","journal-title":"PLoS One"},{"key":"4009_CR16","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-007-0233-x","volume":"133","author":"Wedding","year":"2007","unstructured":"Wedding U, Rohrig B, Klippstein A et al (2007) Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol 133(12):945\u2013950","journal-title":"J Cancer Res Clin Oncol"},{"key":"4009_CR17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0738-3991(02)00149-0","volume":"50","author":"Rehse","year":"2003","unstructured":"Rehse B, Pukrop R (2003) Effects of psychosocial interventions on quality of life in adult cancer patients: meta-analysis of 37 published controlled outcome studies. Patient Educ Couns 50(2):8","journal-title":"Patient Educ Couns"},{"key":"4009_CR18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0738-3991(99)00029-4","volume":"37","author":"De","year":"1999","unstructured":"De Boer MF, Ryckman RM, Pruyn JF, Van den Borne HW (1999) Psychosocial correlates of cancer relapse and survival: a literature review. Patient Educ Couns 37(3):215\u2013230","journal-title":"Patient Educ Couns"},{"key":"4009_CR19","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0895-4356(99)00098-0","volume":"52","author":"Coebergh","year":"1999","unstructured":"Coebergh JW, Janssen-Heijnen ML et al (1999) Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993\u20131996. J Clin Epidemiol 52(12):1131\u20131136","journal-title":"J Clin Epidemiol"},{"key":"4009_CR20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-5347(01)65964-0","volume":"156","author":"Albertsen","year":"1996","unstructured":"Albertsen PC, Fryback DG, Storer BE et al (1996) The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156(1):127\u2013132","journal-title":"J Urol"},{"key":"4009_CR21","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/01.ju.0000108138.36333.09","volume":"171","author":"Froehner","year":"2004","unstructured":"Froehner M, Koch R, Litz R et al (2004) Which conditions contributing to the Charlson score predict survival after radical prostatectomy? J Urol 171(2 Pt 1):697\u2013699","journal-title":"J Urol"},{"key":"4009_CR22","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23(8):1296\u20131310","journal-title":"Clin Ther"},{"key":"4009_CR23","first-page":"2","volume":"36","author":"Wagner","year":"2014","unstructured":"Wagner HO (2014) Medikamente m\u00f6glichst reduzieren. Allgemeinarzt 36(1):2","journal-title":"Allgemeinarzt"},{"key":"4009_CR24","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","volume":"23","author":"Bellera","year":"2012","unstructured":"Bellera CA, Rainfray M, Mathoulin-Pelissier S et al (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23(8):2166\u20132172","journal-title":"Ann Oncol"},{"key":"4009_CR25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.22495","volume":"109","author":"Mohile","year":"2007","unstructured":"Mohile SG, Bylow K, Dale W et al (2007) A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109(4):802\u2013810","journal-title":"Cancer"},{"key":"4009_CR26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.suronc.2009.11.008","volume":"19","author":"Balducci","year":"2010","unstructured":"Balducci L, Colloca G, Cesari M, Gambassi G (2010) Assessment and treatment of elderly patients with cancer. Surg Oncol 19(3):117\u2013123","journal-title":"Surg Oncol"},{"key":"4009_CR27","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s00108-009-2518-4","volume":"50","author":"Berthold","year":"2009","unstructured":"Berthold HK, Steinhagen-Thiessen E (2009) Drug therapy in the elderly:what are the problems? What are the dos and don\u2019ts? Internist 50(12):1415\u20131424","journal-title":"Internist"},{"key":"4009_CR28","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1470-2045(14)70018-X","volume":"15","author":"Droz","year":"2014","unstructured":"Droz JP, Aapro M, Balducci L et al (2014) Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15(9):404\u2013414","journal-title":"Lancet Oncol"},{"key":"4009_CR29","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.eururo.2007.12.032","volume":"53","author":"Studer","year":"2008","unstructured":"Studer UE, Collette L, Whelan P et al (2008) Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 53(5):941\u2013949","journal-title":"Eur Urol"},{"key":"4009_CR30","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448\u20134456","journal-title":"J Clin Oncol"},{"key":"4009_CR31","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ijrobp.2011.04.067","volume":"82","author":"Nguyen","year":"2012","unstructured":"Nguyen PL, Chen MH, Beckman JA et al (2012) Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 82(4):1411\u20131416","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4009_CR32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1756287212441234","volume":"4","author":"Aapro","year":"2012","unstructured":"Aapro M, Saad F (2012) Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol 4(2):85\u2013101","journal-title":"Ther Adv Urol"},{"key":"4009_CR33","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","volume":"367","author":"Crook","year":"2012","unstructured":"Crook JM, O\u2019Callaghan CJ, Duncan G et al (2012) Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367(10):895\u2013903","journal-title":"N Engl J Med"},{"key":"4009_CR34","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL et al (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368(14):1314\u20131325","journal-title":"N Engl J Med"},{"key":"4009_CR35","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"Bono","year":"2011","unstructured":"Bono JS de, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005","journal-title":"N Engl J Med"},{"key":"4009_CR36","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, Bono JS de et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138\u2013148","journal-title":"N Engl J Med"},{"key":"4009_CR37","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197","journal-title":"N Engl J Med"},{"key":"4009_CR38","doi-asserted-by":"crossref","unstructured":"Scher H, Fizazi K, Saad F et al (2013) Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. J Clin Oncol 31(6 Suppl)","DOI":"10.1200\/jco.2013.31.6_suppl.6"},{"key":"4009_CR39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411\u2013422","journal-title":"N Engl J Med"},{"key":"4009_CR40","first-page":"939","volume":"10","author":"Guancial","year":"2015","unstructured":"Guancial EA, Roussel B, Bergsma DP et al (2015) Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging 10:939\u2013949","journal-title":"Clin Interv Aging"},{"key":"4009_CR41","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/cncr.26646","volume":"118","author":"Extermann","year":"2012","unstructured":"Extermann M, Boler I, Reich RR et al (2012) Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118(13):3377\u20133386","journal-title":"Cancer"},{"key":"4009_CR42","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.eururo.2008.07.078","volume":"55","author":"Italiano","year":"2009","unstructured":"Italiano A, Ortholan C, Oudard S et al (2009) Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 55(6):1368\u20131375","journal-title":"Eur Urol"},{"key":"4009_CR43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","volume":"26","author":"Berthold","year":"2006","unstructured":"Berthold DR, Pond GR, Soban F et al (2006) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26(2):242\u2013245","journal-title":"J Clin Oncol"},{"key":"4009_CR44","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"Bono","year":"2010","unstructured":"Bono JS de, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147\u20131154","journal-title":"Lancet"},{"key":"4009_CR45","first-page":"30","volume":"32","author":"Galsky","year":"2014","unstructured":"Galsky MD, Krege S, Lin CC et al (2014) Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urol Oncol 32(1):30 15\u201321","journal-title":"Urol Oncol"},{"key":"4009_CR46","first-page":"S0022","volume":"pii","author":"Gupta","year":"2015","unstructured":"Gupta A, Long JB, Chen J et al (2015) Risk of vascular toxicity with platinum based chemotherapy in elderly patients with bladder cancer. J Urol pii: S0022-5347(15)04708-4","journal-title":"J Urol"},{"key":"4009_CR47","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J et al (2011) Treatment of patients with metastatic urothelial cancer \u201eunfit\u201c for Cisplatin-based chemotherapy. J Clin Oncol 29(17):2432\u20132438","journal-title":"J Clin Oncol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-4009-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-015-4009-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-4009-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T22:54:17Z","timestamp":1567464857000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-015-4009-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["4009"],"URL":"https:\/\/doi.org\/10.1007\/s00120-015-4009-7","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}